Evidence-Based Formulation

Why These Nutrients. Why Now.

Every ingredient in Rebound Vitamins is selected for a specific, documented role in alcohol withdrawal recovery. Here is the clinical and scientific rationale behind each one.

The Nutritional Crisis Hidden Inside Every Withdrawal

Alcohol use disorder creates a predictable, severe pattern of micronutrient depletion. Ethanol impairs absorption, accelerates excretion, and displaces nutrient-dense food — leaving patients entering withdrawal with deficits that directly worsen seizure risk, neurological injury, and recovery outcomes.

Rebound Vitamins was formulated to address this pattern comprehensively — not just the three nutrients most protocols require, but the full spectrum of deficiencies documented in the peer-reviewed literature.

Neurological Protection100 mg per tablet

#01Thiamine (Vitamin B1)

Clinical Rationale

Thiamine deficiency is present in up to 80% of patients with alcohol use disorder. Ethanol blocks thiamine absorption at the intestinal level and impairs hepatic storage. Without adequate thiamine, pyruvate cannot enter the Krebs cycle — neurons starve of ATP, producing the classic triad of Wernicke's encephalopathy: ophthalmoplegia, ataxia, and confusion. The 100 mg oral dose in Rebound matches the standard prophylactic dose recommended by ASAM and UCSF CIWA-Ar guidelines.

Mechanism of Action

Thiamine pyrophosphate (TPP) is the active coenzyme for pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, and transketolase — all critical for neuronal energy metabolism and the pentose phosphate pathway.

Key References
  1. 1.Thomson AD et al. Alcohol Alcohol. 2002;37(6):513–521.
  2. 2.Day E et al. Cochrane Database Syst Rev. 2013;7:CD004033.
Hematological & Neurological Support0.4 mg per tablet

#02Folate (Vitamin B9)

Clinical Rationale

Chronic alcohol use impairs folate absorption in the jejunum and increases urinary folate excretion two- to threefold. Folate deficiency is the most common vitamin deficiency in patients with AUD, contributing to macrocytic anemia, hyperhomocysteinemia, and neurological dysfunction. The 0.4 mg dose provides daily repletion consistent with standard supplementation guidelines.

Mechanism of Action

Folate is essential for one-carbon metabolism, DNA synthesis, and the methylation cycle. Deficiency elevates homocysteine — an independent neurotoxin — and impairs myelin synthesis and repair.

Key References
  1. 1.Halsted CH et al. Alcohol. 2002;27(3):169–172.
  2. 2.Cravo ML et al. Am J Clin Nutr. 1996;63(2):220–224.
Seizure Threshold & Neuromuscular StabilityTherapeutic oral dose

#03Magnesium

Clinical Rationale

Hypomagnesemia is present in 30–80% of patients with AUD and is directly linked to lowered seizure threshold during withdrawal. Alcohol increases renal magnesium wasting and reduces intestinal absorption. Oral magnesium supplementation supports benzodiazepine efficacy by stabilizing NMDA receptor activity and reducing neuromuscular excitability throughout the withdrawal period.

Mechanism of Action

Magnesium acts as a physiological NMDA receptor antagonist. During alcohol withdrawal, NMDA receptors are upregulated — magnesium deficiency removes a key brake on excitatory neurotransmission, increasing seizure and delirium risk.

Key References
  1. 1.Elisaf M et al. J Trace Elem Med Biol. 1995;9(4):210–214.
  2. 2.Sarai M et al. Alcohol Alcohol. 2013;48(2):177–183.
Metabolic RecoveryComplete daily profile

#04Full B-Complex (B2, B3, B5, B6, B12)

Clinical Rationale

Patients with AUD are broadly malnourished across the entire B-vitamin spectrum. Riboflavin (B2) deficiency causes peripheral neuropathy and mucositis. Niacin (B3) deficiency produces pellagra-like symptoms. Pyridoxine (B6) deficiency impairs GABA synthesis — directly relevant to withdrawal severity. B12 deficiency contributes to megaloblastic anemia and subacute combined degeneration of the spinal cord. Rebound addresses all of these with a complete B-complex rather than isolated supplementation.

Mechanism of Action

B vitamins serve as coenzymes across the citric acid cycle, electron transport chain, and neurotransmitter synthesis pathways. B6 is the direct precursor to pyridoxal phosphate, the coenzyme for glutamate decarboxylase — the enzyme that synthesizes GABA from glutamate.

Key References
  1. 1.Leevy CM, Baker H. Am J Clin Nutr. 1968;21(11):1325–1328.
  2. 2.Sechi G, Serra A. Lancet Neurol. 2007;6(5):442–455.
Oxidative Stress ReductionAntioxidant support dose

#05Vitamin C (Ascorbic Acid)

Clinical Rationale

Chronic alcohol consumption generates reactive oxygen species (ROS) that deplete ascorbic acid stores. Oxidative stress during withdrawal contributes to hepatocellular injury, neuroinflammation, and impaired immune function. Vitamin C supplementation supports glutathione recycling and collagen synthesis during the recovery period.

Mechanism of Action

Ascorbic acid is a direct free-radical scavenger and a cofactor for dopamine β-hydroxylase — the enzyme that converts dopamine to norepinephrine. It also regenerates vitamin E from its oxidized form, amplifying antioxidant capacity.

Key References
  1. 1.Lecomte E et al. Alcohol Clin Exp Res. 1994;18(6):1444–1448.
Immune & Musculoskeletal SupportDaily maintenance dose

#06Vitamin D

Clinical Rationale

Vitamin D deficiency is highly prevalent in patients with AUD due to reduced sun exposure, impaired hepatic 25-hydroxylation, and poor dietary intake. Deficiency is associated with increased fracture risk, impaired immune function, and depression — all relevant to the withdrawal and early recovery period.

Mechanism of Action

Vitamin D3 (cholecalciferol) is converted to 25(OH)D in the liver and then to the active 1,25(OH)2D in the kidney. The active form binds nuclear vitamin D receptors in over 200 cell types, regulating calcium homeostasis, immune modulation, and neurotrophic factor expression.

Key References
  1. 1.Santaolalla F et al. Nutr Res. 2010;30(7):498–503.
Membrane ProtectionAntioxidant support dose

#07Vitamin E (Tocopherol)

Clinical Rationale

Alcohol-induced oxidative stress depletes fat-soluble antioxidants including vitamin E. Tocopherol protects neuronal and hepatic cell membranes from lipid peroxidation — a key mechanism of alcohol-related organ damage. Supplementation supports membrane integrity during the acute withdrawal and recovery phase.

Mechanism of Action

Alpha-tocopherol intercepts lipid peroxyl radicals in cell membranes, terminating chain reactions that would otherwise destroy polyunsaturated fatty acids. It works synergistically with vitamin C, which regenerates oxidized tocopherol.

Key References
  1. 1.Meagher EA et al. N Engl J Med. 2001;344(9):665–672.
Immune Function & Wound HealingDaily maintenance dose

#08Zinc

Clinical Rationale

Zinc deficiency is common in AUD due to reduced dietary intake, impaired intestinal absorption, and increased urinary zinc excretion. Zinc is required for over 300 enzymatic reactions and is critical for immune function, wound healing, and taste/smell perception — all impaired in patients with AUD. Zinc also plays a role in modulating NMDA receptor activity, relevant to withdrawal neurotoxicity.

Mechanism of Action

Zinc is a structural component of zinc-finger proteins, a cofactor for alcohol dehydrogenase (the primary enzyme of ethanol metabolism), and an allosteric modulator of NMDA and GABA-A receptors — making it directly relevant to the neurochemistry of withdrawal.

Key References
  1. 1.Prasad AS. J Trace Elem Med Biol. 2014;28(4):364–371.
  2. 2.Kessler H et al. J Neural Transm. 2005;112(3):397–406.

One Tablet. Complete Coverage.

Rather than requiring clinicians to order four separate supplements — thiamine, folic acid, magnesium, and a multivitamin — Rebound consolidates the complete evidence-based nutritional protocol into a single tablet taken twice daily during active withdrawal, then once daily through six weeks of recovery.

Days 1–5
1 tablet BID (twice daily)
Active withdrawal repletion
Day 6 – Week 6
1 tablet daily
Maintenance and recovery support
Emergency Department Reference

Emergency Department: Treatment, Diagnostic & Billing Codes

A complete reference for ED providers treating alcohol intoxication, withdrawal, and AUD — covering diagnostic codes, treatment procedures, SBIRT screening, and discharge documentation to support maximum insurance reimbursement.

ED Revenue Opportunity
$800–$4,500+

Estimated reimbursement range per ED encounter for alcohol-related presentation, depending on complexity level, procedures performed, and payer mix. Proper code selection and SBIRT documentation are the primary levers.

Code
Type
Description
Notes
F10.120
ICD-10
Alcohol abuse with intoxication, uncomplicated
Use for acute intoxication without dependence diagnosis
F10.121
ICD-10
Alcohol abuse with intoxication delirium
Altered mental status, agitation, disorientation
F10.220
ICD-10
Alcohol dependence with intoxication, uncomplicated
Known AUD with acute intoxication
F10.230
ICD-10
Alcohol dependence with withdrawal, uncomplicated
CIWA-Ar score < 10; mild withdrawal
F10.231
ICD-10
Alcohol dependence with withdrawal delirium (DTs)
CIWA-Ar ≥ 15 with delirium; highest acuity
F10.232
ICD-10
Alcohol dependence with withdrawal with perceptual disturbance
Hallucinations without frank delirium
F10.239
ICD-10
Alcohol dependence with withdrawal, unspecified
Use when severity not yet established
F10.10
ICD-10
Alcohol use disorder, mild (unspecified)
Secondary diagnosis; supports SBIRT billing
F10.20
ICD-10
Alcohol use disorder, moderate/severe
Secondary diagnosis; supports H0011 vs H0010 selection
Z87.891
ICD-10
Personal history of alcohol use disorder
Aftercare and follow-up encounters
E51.2
ICD-10
Wernicke's encephalopathy
Document when thiamine deficiency triad present
E61.2
ICD-10
Magnesium deficiency
Pair with serum Mg lab; supports IV Mg administration
R41.3
ICD-10
Other amnesia / cognitive impairment
Korsakoff syndrome sequela; secondary code
G31.2
ICD-10
Degeneration of nervous system due to alcohol
Chronic neurological sequelae of AUD

* Rates are illustrative estimates. Actual reimbursement varies by payer, state, and contract. Verify with your billing department.

Discharge Documentation & Insurance Reimbursement

Proper discharge documentation is the single most important factor in recouping full reimbursement for an alcohol-related ED encounter. The following elements should be present in every discharge summary.

1
CIWA-Ar Score Documentation

Record the initial CIWA-Ar score and any repeat scores during the visit. The score directly supports E&M level selection (99283 vs. 99284 vs. 99285) and justifies benzodiazepine administration. A score ≥ 10 supports moderate complexity; ≥ 15 supports high complexity.

2
Blood Alcohol Level (BAL)

Document the quantitative serum ethanol level (CPT 82055). The BAL at presentation supports the primary ICD-10 diagnosis code selection and establishes medical necessity for monitoring and IV fluids.

3
Thiamine Administration

Document IV or IM thiamine administration (J3490) with dose and route. Note any signs of Wernicke's encephalopathy (E51.2). Thiamine must be given before glucose in suspected deficiency — document the sequence.

4
Magnesium Level & Replacement

Document serum magnesium (CPT 83735) and any IV magnesium sulfate administered (J3475 per 500 mg). Hypomagnesemia (E61.2) as a secondary diagnosis supports the administration and the supplementation recommendation at discharge.

5
SBIRT Screening Tool & Score

Document the screening tool used (AUDIT, AUDIT-C, DAST-10), the score, and the brief intervention provided. This is required to bill 99408/99409 or G0396/G0397. The intervention must be face-to-face and documented as a separate service.

6
Discharge Medication Reconciliation

List all medications prescribed or recommended at discharge, including oral thiamine, folate, magnesium, and Rebound Vitamins. Documenting a structured nutritional supplementation plan supports the medical necessity narrative for the encounter and any follow-up claims.

7
Referral & Follow-Up Documentation

Document referrals to outpatient AUD treatment, MAT programs, or primary care. A documented referral supports the SBIRT billing codes and demonstrates care coordination — a factor in value-based reimbursement models and readmission reduction programs.

8
Principal vs. Secondary Diagnosis Sequencing

The principal diagnosis drives DRG assignment for inpatient admissions and APC assignment for outpatient ED visits. Sequence the most resource-intensive condition first (e.g., F10.231 for DTs rather than F10.120 for uncomplicated intoxication) to capture the correct payment weight.

Payer-Specific Billing Notes

Medicare

SBIRT codes G0396/G0397 are covered under Medicare Part B when billed by a physician, NP, or PA. The service must be face-to-face and documented as a distinct service from the E&M visit. Use modifier -25 on the E&M code to indicate a separately identifiable service.

Medicaid

Coverage for SBIRT (H0049/H0050) varies by state plan. Most states cover at least one SBIRT screening per year. Brief intervention units (H0050) are billed per 15 minutes. Verify your state's specific billing rules and any prior authorization requirements.

Commercial Insurance

Most commercial plans cover SBIRT under preventive services (ACA §2713) with no cost-sharing when billed with a Z-code secondary diagnosis (Z13.89 — encounter for screening for other disorder). Confirm payer-specific coding requirements.

Uninsured / Self-Pay

For uninsured patients, document the full encounter as if billing insurance. This creates a complete medical record that supports any future coverage determination, Medicaid retroactive eligibility, or charity care application.

Ready to integrate Rebound into your protocol?

Review the full CIWA-Ar integration guide or order for your practice today.

Medical Disclaimer: This page is intended as a clinical reference for licensed healthcare providers. Rebound Vitamins is a nutritional supplement, not a pharmaceutical product, and does not replace clinical judgment or institutional protocol. IV Thiamine and IV Magnesium remain indicated when clinically required regardless of oral supplementation. Billing code descriptions and estimated rates are provided for reference only and do not constitute billing advice. Actual reimbursement varies by payer, state, and contract. Always verify codes with your compliance officer, billing department, or payer. These statements have not been evaluated by the Food and Drug Administration. — Wallace Peoples, C.E.O., W.Peoples Pharmaceuticals